Literature DB >> 15316451

Tissue Doppler imaging as a guide to resynchronization therapy in patients with congestive heart failure.

Peter Søgaard1, Christian Hassager.   

Abstract

PURPOSE OF REVIEW: Cardiac resynchronization therapy is a nonpharmacological treatment option in patients with heart failure and left bundle branch block but response rates are still disappointing. RECENT
FINDINGS: Extent of mechanical left ventricular asynchrony as detected by tissue Doppler imaging has emerged as an independent predictor of outcome to CRT. In addition, long-term therapy delivery may be further improved through optimized lead positioning and pacemaker programming.
SUMMARY: Tissue Doppler imaging should be included in the evaluation of potential CRT candidates but standardized evaluation criteria have not yet been provided.

Entities:  

Mesh:

Year:  2004        PMID: 15316451     DOI: 10.1097/01.hco.0000131536.70775.68

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

1.  Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study.

Authors:  András Csaba Nagy; Zsuzsanna Cserép; Edina Tolnay; Tamás Nagykálnai; Tamás Forster
Journal:  Pathol Oncol Res       Date:  2008-03-15       Impact factor: 3.201

2.  New aspects on the assessment of left ventricular dyssynchrony by tissue Doppler echocardiography: comparison of myocardial velocity vs. displacement curves.

Authors:  N Bogunovic; D Hering; F van Buuren; D Welge; B Lamp; D Horstkotte; L Faber
Journal:  Int J Cardiovasc Imaging       Date:  2009-08-05       Impact factor: 2.357

3.  Baseline tissue Doppler imaging-derived echocardiographic parameters and left ventricle reverse remodelling following cardiac resynchronization therapy introduction.

Authors:  Jerzy Wiliński; Danuta Czarnecka; Wiktoria Wojciechowska; Małgorzata Kloch-Badełek; Marek Jastrzębski; Bogumiła Bacior; Tomasz Sondej; Aleksander Kusiak
Journal:  Arch Med Sci       Date:  2011-11-08       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.